Andrés R. S.
- Country
- Spain
- Department
- Oncology
Research Overview
- Phase 3 Study Comparing Rinatabart Sesutecan Versus Investigator's Choice in Patients With Recurrent or Progressive Endometrial Cancer Following Platinum-Based and PD(L)-1 Therapy
- Phase 3 Randomized Open‑Label Study of INCB123667 Versus Investigator’s Choice Chemotherapy Combination in Platinum‑Resistant Ovarian Cancer with Cyclin E1 Overexpression
- Phase 3 Randomized Open-Label Trial of Tisotumab Vedotin Versus Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
Data & Insights
Has run more than one trial at 212 of 348 partner sites.
Specializations
Gynecologic Oncology
This investigator specializes in treating various forms of gynecological cancers, with particular focus on ovarian cancer and its variants including high-grade serous, fallopian tube, and primary peritoneal cancers.
- Advanced Ovarian Cancer Treatment
- BRCA-Mutated Cancers
- Platinum-Resistant Disease
The investigator works with novel therapeutic approaches including maintenance treatments and targeted therapies for gynecologic malignancies.
Sarcoma Research
The investigator has extensive experience in treating soft tissue sarcomas and bone tumors, including various subtypes such as leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma.
- Advanced/Metastatic Sarcomas
- Combination Therapy Approaches
- Novel Treatment Modalities
Their work includes innovative therapeutic combinations incorporating radiation therapy and targeted agents.
Experimental Therapeutics
The investigator conducts research on novel therapeutic agents and biomarker-driven treatments across multiple cancer types.
- Targeted Therapies
- Immunotherapy Applications
- Combination Treatment Strategies
Their work encompasses early-phase clinical trials and the development of personalized treatment approaches.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.